Nippon Express Italia Acquires GDP Certification for Company-owned Warehouse near Milan Malpensa Airport
TOKYO, July 14, 2021 /PRNewswire/ -- Nippon Express Italia S.P.A. (hereinafter "NE Italy"), a local subsidiary of Nippon Express Co., Ltd., obtained Good Distribution Practice (GDP) certification from the certification body CERTIQUALITY S.r.l., effective May 25, for its company-owned warehouse near Milan Malpensa Airport, evidencing its compliance with GDP standards for the proper distribution of pharmaceuticals established by the European Commission.
Photo: Warehouse interior
Italy is a key global manufacturer of pharmaceuticals, accounting for 12% of the world's pharmaceutical production and 22% of Europe's. Pharmaceutical manufacturing is a growth industry domestically as well, having achieved 168% growth over the past ten years.
NE Italy has constructed new temperature-controlled facilities equipped with cooling units to maintain 2 - 8 C (20 m2) and 15 - 25 C (470 m2) temperature ranges within its company-owned warehouse in Lainate, located about 30 km southeast of Milan Malpensa Airport. This will allow NE Italy to meet the logistics needs of customers in the pharmaceutical industry by combining temporary storage services using these facilities with Nippon Express's temperature-controlled international transport services.
Nippon Express will be further enhancing its services to meet increasingly sophisticated and diverse pharmaceutical logistics needs and bolstering its efforts on behalf of the pharmaceutical industry, positioned as a priority industry in its current business plan.
- Name and address of branch
Name: Milano-Lainate Branch, Nippon Express Italia S.P.A.
Address: Via Juan Manuel Fangio 11, 20020 Lainate (MI), Italy
Nippon Express website: http://www.nipponexpress.com/
Official LinkedIn account: NIPPON EXPRESS GROUP
SOURCE Nippon Express Co., Ltd.
Upcoming Life Sciences Events
- August 2021
- Biotechgate Digital Partnering
- September 2021
- Swiss Biotech Day 2021
- Digital RESI
Latest company news
The World's First Study Of A Combination Between The AstraZeneca Vaccine And The First Component Of The Sputnik V Vaccine (Sputnik Light) In Azerbaijan Shows No Serious Adverse Events Or COVID Infection Cases Following The Vaccination